Kolexia
Parzy Aurelie Gastro-entérologie
Parzy Aurelie
Gastro-entérologie
Centre François-Baclesse
Caen, France
39 Activités
78 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Tumeurs de l'anus Métastase tumorale Récidive tumorale locale Tumeurs du pancréas Tumeurs colorectales Tumeurs de l'oesophage Cellules tumorales circulantes

Collaborateurs

Voir plus
Galais Marie-Pierre
Galais Marie-Pierre
Centre François-Baclesse, Caen, France
Corbinais Stephane
Corbinais Stephane
Centre François-Baclesse, Caen, France
Dos Santos Melanie
Dos Santos Melanie
Hôpital Côte de Nacre, Caen, France
Bouhier-Leporrier Karine
Bouhier-Leporrier Karine
Centre François-Baclesse, Caen, France

Industries

Voir plus
Servier
10 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2023
Ipsen
3 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
1617P PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
GASPAR: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
Essai Clinique (Centre François-Baclesse)   22 décembre 2022
1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.
2022 ASCO Annual Meeting I   02 juin 2022
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
BMC cancer   12 mai 2022
Epitopes-HPV02: Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.
Essai Clinique (CHU Besançon)   10 mai 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
European journal of cancer (Oxford, England : 1990)   04 janvier 2022
508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
British journal of cancer   10 juin 2021